Compare Moderna, Inc. (MRNA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Moderna, Inc. trades at $221.75 (market cap $90.35B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Moderna, Inc. is far larger — about 18× Travere Therapeutics Inc. Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MRNA | TVTX | |
|---|---|---|
Market Cap | $90.35B | $5.02B |
Volume | 16,579,584 | 2,060,842 |
Sector | Health | Health |
52-Week High | $226.30 | $67.52 |
52-Week Low | $22.36 | $26.79 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $86.50B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal and recent Nasdaq-100 inclusion driving momentum. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with a net income margin of -142.58% and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock's 500% rally in 2026 has pushed valuations to elevated levels with a P/S of 38.5, creating divergence between technical strength and financial performance.
The outlook remains polarized with Nasdaq inclusion providing institutional support but valuation concerns capping upside. Investment opportunity lies in the cancer vaccine pipeline, while risks include sustained profitability challenges and competitive pressures. Analyst consensus at $115.70 suggests significant downside from current levels, with only 28% recommending buy ratings amid ongoing operational cash flow deficits.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
